Our Team

Each Partner brings extensive industry knowledge, unrivaled relationships and substantial deal experience, resulting in a team of the industry's most sought after advisors

Jason W. Lee

Jason Lee joined Centerview Partners in 2012 and is a Partner in the San Francisco office.  At Centerview, Mr. Lee has advised a broad range of life science companies across strategic advisory assignments and transactions exceeding $130 billion in value.

Notable transactions include:
  • 2021: GW Pharmaceuticals on its sale to Jazz Pharmaceuticals for $7.2 billion, Dicerna Pharmaceuticals on its sale to Novo Nordisk for $3.3 billion, Constellation Pharmaceuticals on its sale to MorphoSys for $1.7 billion, Lengo Therapeutics on its sale to blueprint for up to $465 million
  • 2020:  Immunomedics on its sale to Gilead for $21 billion, Forty Seven Therapeutics on its sale to Gilead for $4.9 billion, Eidos Therapeutics on its $1.1 billion sale of the publicly-traded minority shares to BridgeBio, Pionyr on its option transaction with Gilead
  • 2019:  Array BioPharma on its sale to Pfizer for $11.8 billion, Ra Pharma on its sale to UCB for $2.5 billion, ArQule on its sale to Merck for $2.7 billion, Synthorx on its sale to Sanofi for $2.5 billion, Peloton Therapeutics on its sale to Merck for up to $2.2 billion
  • 2018:  Tesaro on its sale to GSK for $5.1   billion, AveXis on its sale to Novartis for $8.7 billion, ARMO on its sale to Eli Lilly for $1.6 billion, Syntimmune on its sale to Alexion for up to $1.2 billion
  • 2017:  Kite Pharma on its sale to Gilead for $11.9 billion
  • 2016:  Relypsa on its sale to Galenica for $1.5 billion, Raptor on its sale to Horizon for $0.8 billion, XenoPort on its sale to Arbor for $500 million
  • 2015:  Pharmacyclics on its sale to AbbVie for $21 billion, Dyax on its sale to Shire for $6.6 billion
  • 2014:  InterMune on its sale to Roche for $8.9 billion, Avanir on its sale to Otsuka for $3.5 billion, Cadence on its sale to Mallinckrodt for $1.3 billion
  • 2013:  Onyx on its sale to Amgen for $10.4 billion, Optimer and Trius on their sale to Cubist for $0.8 billion and $0.8 billion, respectively, MAP Pharmaceuticals on its sale to Allergan for $1 billion

Mr. Lee holds an M.B.A. from Cornell University and a B.S. in Microbiology and Molecular Genetics from University of California, Los Angeles.
Centerview Partners takes a “One Firm” approach to deliver unmatched intellectual capital and integrity to all of our clients. We have industry-leading expertise in:

Centerview is honored to partner with leading charitable organizations in active support of our charities:

  • Arts Connection
  • NY Cares
  • Bottomless Closet
Celsius Network LLC
Announced: Q3 2022
Status: Pending

Investment banker to Celsius on its initiation of voluntary chapter 11 proceedings
View All
New York

Centerview Partners LLC

31 West 52nd Street

22nd Floor

New York, New York 10019

(212) 380-2650 | Tel
(212) 380-2651 | Fax

Centerview Partners UK LLP

100 Pall Mall

3rd Floor

London SW1Y 5NQ

02074099700 | Tel
02074099704 | Fax

Centerview Partners France SCS

16 Avenue Matignon

4th Floor

Paris 75008

0180200620 | Tel
0180200621 | Fax
Palo Alto

Centerview Partners LLC

600 Ramona St.

Suite 300

Palo Alto, California 94301

(650) 822-5800 | Tel
(650) 822-5801 | Fax
San Francisco

Centerview Partners LLC

555 California Street

Suite 4300

San Francisco, California 94104

(415) 400-0900 | Tel
(415) 400-0901 | Fax

Copyright © 2008 - 2022 Centerview Partners Holdings LP. All Rights Reserved. | Privacy and Other Notices

Centerview Partners LLC, member SIPC